Meadowview Healthcare And Rehab Medicare and Medicaid Location: 825 North Gaskill, Huntsville, Arkansas 72740 Ratings: Phone: (479) 738-2021 |
News Archive
Net sales decreased 8.8% to $123.9 million in the second quarter of 2009 compared with $135.8 million in the second quarter of 2008. Income from operations was $16.6 million in the second quarter of 2009, compared to $16.0 million in the second quarter of 2008. Net loss was $1.2 million in the second quarter of 2009, compared with a net loss of $1.3 million in the second quarter of 2008.
Today, the George Washington University Heart and Vascular Institute and The Wireless Foundation, in partnership with the D.C. Fire and Emergency Medical Services, announced their innovative public health initiative, which will improve cardiac care in the nation's capital.
The New York Times reports the Justice Department and senior White House officials are debating legal action against Colorado and Washington, which could undermine voter-approved initiatives. Meanwhile, a USA Today/Gallup Poll shows Americans are divided on decriminalization efforts but believe the federal government should not intervene after states vote to take that step.
In a groundbreaking paper currently available on the bioRxiv* preprint server, the researchers from the Washington University School of Medicine and Stony Brook University showed how nucleocapsid protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is dynamic, disordered and phase separates with RNA – informing, in turn, the discovery of drugs that disrupt viral packaging.
Regulus Therapeutics Inc. announced today that it has obtained exclusive rights from the University of Wuerzburg to intellectual property covering methods for modulating microRNA-21. Regulus scientists and collaborators have shown that microRNA-21, (miR-21), is dysregulated in mouse models of cardiac disease and fibrosis, and that antagonizing miR-21 with therapeutic oligonucleotides targeting miR-21 inhibits fibrosis and attenuates cardiac function in such models. Regulus is currently developing a microRNA therapeutic targeting miR-21 as an anti-fibrotic therapy.
› Verified 6 days ago